Phase 2 N=110 Computer-Assisted Intervention for Smoking During Pregnancy
Smoking
Primary: Smoking Behavior (Self-report Confirmed by Expired Breath CO) — 2; 7; 2; 5 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=34 Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer
Thrombocytopenia · Neutropenia · Lymphopenia
Primary: Chemotherapy Cycles During Which the Platelet Count Measures Below 50,000/mm3 — 20.0; 11.7; 21.5 Percentage of cycles
Phase 2 N=60 Ranibizumab and Reduced Fluence PDT for AMD
Macular Degeneration
Primary: The Percentage of Patients With Less Than 15 Letters of ETDRS Visual Loss at 12 Months. — 22; 14 percentage of participants
Phase 2 N=76 S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
Breast Cancer
Primary: Survival at 1 Year — 93 percentage of patients
Phase 2 N=28 Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance
Type 2 Diabetes · Insulin Resistance · Metabolic Syndrome
Primary: Change From Baseline in Insulin Sensitivity as Measured by Glucose Infusion Rate (GIR) — 17.95; 1.68 micromols/kg of FFM/minute — p=<0.001
Phase 2 N=20 Effects of L-arginine Supplementation in Adults With Moderate to Severe Asthma
Asthma
Primary: Number of Asthma Exacerbations in Three Months — 30; 31 exacerbations
Phase 2 N=308 Late Phase 2 Study of OPC-12759 Ophthalmic Suspension
Dry Eye Syndromes
Primary: Change in Fluorescein Corneal Staining (FCS) Score From Baseline to Last Observation Carried Forward (LOCF) — -3.5; -3.7; -1.8 FCS score — p=0.001
Phase 2 N=145 Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women
Neoplasms, Ovarian
Primary: Progression-free Survival (PFS) — 18.1; 18.1 months
Phase 2 N=49 Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration
Exudative Age-Related Macular Degeneration
Primary: Mean Reduction From Baseline in Central Subfield (CSF) Retinal Thickness at Week 4 — 514.2; 551.8; -12.1; 199.9 microns
Phase 2 N=61 Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer
Colorectal Neoplasms
Primary: Percentage of Participants With Objective Response: Phase 2 — 28.6; 48.8; 39.0 Percentage of participants — p=0.9726
Phase 2 N=10 Pilot Study Evaluating the Safety and Performance of the GeNO NITROsyl Delivery System for Inhaled Nitric Oxide
Pulmonary Arterial Hypertension
Primary: Incidence and Severity of Treatment Emergent Adverse Events; Unanticipated Adverse Device Effects and Changes From Baseline to End-of-study in Clinical Lab Parameters…
Phase 2 N=70 AtriCure Exclusion of the LAA in Patients Undergoing Concomitant Cardiac Surgery
Left Atrial Appendage Exclusion
Primary: Rate of Device Related Serious Adverse Events — 0 Number of participants
Phase 2 N=103 Free Venlafaxine Treatment for Marijuana Addiction and Depression - 1
Depression · Marijuana Abuse
Primary: Two Consecutive Weeks of Marijuana Abstinence — 19; 6 participants — p=<0.01
Phase 2 N=7 TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients
Influenza
Primary: Number of Participants With Adverse Events (AEs), Drug Specific AEs or AEs Resulting in Treatment Interruption — 1; 1; 1 number of participants with AEs
Phase 2 N=49 A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection
Hepatitis C, Chronic
Primary: Change From Baseline in Log 10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level at Day 15 — 6.61; 6.21; 6.15; 6.65 log10 IU/ml